VivoSim Labs (VIVS) Research & Development (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Research & Development of $1.1 million for Q1 2026, up 30.97% year-over-year from $859000.0 in Q1 2025, and down 1.32% quarter-over-quarter from $1.1 million in Q4 2025.
VivoSim Labs (VIVS) Research & Development (2011 - 2026) Analysis & Trends
VivoSim Labs' Research & Development history runs 16 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Research & Development rose 30.97% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $4.2 million (down 16.64% YoY), while the FY2026 annual figure was $4.2 million, down 16.64% from the prior year.
- Research & Development for Q1 2026 stood at $1.1 million, down from $1.1 million in the prior quarter.
- The five-year high for Research & Development was $5.4 million in Q1 2023, with the low at $859000.0 in Q1 2025.
- The 5-year median for Research & Development is $1.1 million (2025), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development surged 380.09% in 2023, then tumbled 80.49% in 2024.
- VivoSim Labs' Research & Development stood at $1.2 million in 2022, then grew by 21.01% to $1.4 million in 2023, then grew by 24.13% to $1.8 million in 2024, then sank by 35.96% to $1.1 million in 2025, then slipped by 1.32% to $1.1 million in 2026.
- Business Quant data shows VIVS's Research & Development at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $923000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 97.90 Mn |
| 10 | VivoSim Labs | 1.45 Mn | 1.45 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 923,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 859,000.00 |
| Dec 31, 2024 | 1.78 Mn |
| Sep 30, 2024 | 984,000.00 |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.43 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 5.45 Mn |
| Dec 31, 2022 | 1.19 Mn |
| Sep 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 1.14 Mn |
| Dec 31, 2021 | 926,000.00 |
| Sep 30, 2021 | 679,000.00 |